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Abstract
With the characterization of the human genome, as well as
advances in technology to determine genetic variability across the
genomes of populations, there has been focused effort on the
identification of cancer susceptibility alleles through the use of
genome-wide association studies. These efforts have recently
resulted in identification of a susceptibility locus for breast cancer
by several groups, although the increases in risk are modest. While
genome-wide association studies will probably lead to discoveries
of potentially important previously unstudied pathways in cancer
etiology, the role of the environment, particularly gene–environment
interactions, in breast cancer etiology should not be overlooked.
The ‘known’ risk factors for breast cancer – including ionizing
radiation, breast cancer in a first-degree relative, reproductive
and hormonal factors, alcohol consumption and physical
activity – explain only a portion of the variability in breast
cancer risk. Of these risk factors, other than ionizing radiation,
a family history of breast cancer is responsible for the
greatest increase in risk, with women with a first-degree
relative with breast cancer having twice the risk of those who
do not. A twin study indicated that up to 30% of breast
cancer cases may be due to genetic factors [1]; however, the
‘high-risk’ genes that have been identified, such as BRCA1,
BRCA2, PTEN and p53, explain 20–25% of familial breast
cancer [2] and explain only 5% of total breast cancer [3].
There has thus been focused research on identification of
additional genetic variants responsible for susceptibility to the
disease. Because studies of familial breast cancer have failed
to identify additional genes that infer high risk of breast
cancer, it is thought the remaining genetic factors are likely to
be numerous, with each genetic variant inferring a low to
moderate risk.
There have thus been concerted efforts to identify these
genes, facilitated by the characterization of the human
genome and by rapid advances in technology, which now
allow for interrogation across the genome for differences in
DNA sequence, or single nucleotide polymorphisms (SNPs),
between cases and controls in search of common disease
susceptibility genes. Taking this genome-wide association
(GWA) approach, susceptibility loci for prostate cancer on
chromosome 8q24 were recently identified, alleles which
were also identified using family studies and linkage analysis
(reviewed in [4]).
Most recently, several reports appeared from studies using a
GWA study approach to breast cancer, all replicating
findings for SNPs in fibroblast growth factor receptor 2,
which may be involved in regulating gene expression. It is of
interest that findings were replicated in three studies based in
different types of populations. Using pooled data from more
than 20,000 women with breast cancer and an equal number
of control individuals for the final analysis, the authors of one
study began a three-stage approach by comparing SNPs
among cases with a strong family history of breast cancer
with healthy control individuals to maximize the likelihood of
identifying genes associated with inherited risk [5]. An
additional study published at the same time found similar
results in two data sets of postmenopausal women with
sporadic, or nonfamilial, breast cancer [6], the first set of
which was the Harvard Nurses’ Health Study Nurses Health
Study. A third study was conducted among an Icelandic
population [7], although this study was limited to breast
tumors positive for estrogen receptor expression. In the study
enriched for familial breast cancer [5], it was estimated that
the SNPs identified in fibroblast growth factor receptor 2
explained only 3.6% of familial risk, which would translate to
much lower proportions in nonfamilial breast cancer. Although
the estimates for increases in risk were slight to moderate
(20–60%) in all studies, the variants are common in Caucasian
populations; in the Nurses Health Study and the validation
cohort [6], including primarily postmenopausal women with
breast cancer, it was estimated that the population attributable
risk associated with the variant was 16%.
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These recent studies illustrate the power of GWA studies in
large sample sizes to identify gene variants that may increase
risk of breast cancer, although these are not high-penetrance
genes. Perhaps the greater ramifications for these findings
are that they identify pathways that have not been previously
explored, and they open new doors for basic science and
epidemiologic studies to identify additional causes of breast
cancer.
There are obvious limitations to the GWA approach. First,
although it is probable that the technology currently used
captures the majority of common variants, based upon the
concept of linkage disequilibrium (that blocks of chromo-
somes are  inherited together and can be ‘tagged’ by a
defined, limited set of SNPs within those blocks), it is possible
that some genetic variants that may be important susceptibility
alleles are not covered by the SNPs that are genotyped.
Furthermore, for the majority of genetic variants, it is probable
that effects will only be noted in the context of exposures that
either induce expression of that gene or are associated with
increased or decreased risk in the context of pertinent
exposures. Although we know that breast cancer in a first-
degree relative increases risk of breast cancer, there are also
substantial contributions to risk by reproductive and hormonal
factors, as well as physical activity, alcohol consumption,
radiation to the breast, and some dietary factors, probably the
result of exposures over years or decades.
Failure to account for exposures when searching for genes
that may increase cancer risk may obscure any associations
between genetic variants and risk. For example, N-acetyl-
transferase is an enzyme that metabolizes aromatic amines,
and a large proportion of Caucasians have variants resulting
in slow activity or detoxification. In studies of bladder cancer,
in which aromatic amines are a strong risk factor, there is
generally no main effect of the genotype. It is only among
those who are exposed to aromatic amines that N-acetyl-
transferase slow genotypes are associated with increased
risk, with a recent large study finding elevated risk for the
slow N-acetyltransferase genotype in smokers (odds ratio =
1.6, 95% confidence interval = 1.3–1.9) but no effect (odds
ratio = 0.09, 95% confidence interval = 0.6–1.3) in non-
smokers [8]. We noted similar associations for breast cancer
in relation to smoking [9], which has been confirmed by
recently pooled and meta-analysis [10]. Because of the
complex systems of metabolism of numerous endogenous
and exogenous compounds, it is likely that gene variants
associated with increased risk only among populations with
specific exposures will be overlooked when searching for the
main effects of SNPs.
It is therefore possible that findings from GWA studies for
breast cancer will not result in identification of genes that
explain a large proportion of breast cancer risk; for example,
those with effects that would only be noted among sub-
groups with relevant exposures. A striking example of the
importance of environment in breast cancer etiology is that of
the effects of migration on breast cancer incidence. Japanese
women have the lowest rates of breast cancer in the world,
but their risk rises to that of Caucasians within one or two
generations after migrating to the United States. Obviously,
genetic make-up is not changing, and the preponderance of
increased risk is probably due to external factors [11].
The study of gene–environment interactions in cancer
etiology has always been difficult, due to the complex
mixtures of multiple factors to which humans are exposed and
due to the heterogeneity of carcinogenic pathways. The
investigation of the effects of common variants on breast
cancer risk, without consideration of epidemiologic factors
and exposures, may therefore not be as productive as
application of the GWA approach to other outcomes, such as
predicting patient outcomes following radiation and/or
chemotherapy for cancer. In these situations, the key
exposures (therapeutic agents) are known and can be
measured, and SNPs that may predict severe toxicity and or
disease recurrence among patients who receive treatment
may clearly reflect these gene–environment interactions. It is
probable that, in the coming years, networks of genes that
mediate treatment outcomes will be elucidated, and GWA
studies in the context of clinical trials will lead to pathways to
aid in personalized therapeutics.
Although GWA studies may reveal some previously unknown
variants to be important in cancer risk, the further elucidation
of the complex interactions between multiple genes and
environmental exposures should not be overlooked. If GWA
studies do not result in finding major genes that increase the
risk of breast cancer, or that replicate those from candidate
genes previously studied in the context of environmental
exposures, there is a possibility for disillusionment with the
study of genetic variability in relation to cancer risk. This could
result in a movement away from hypothesis-driven evaluation
of the effects of genetic variability on relationships between
exposures and cancer risk, and could squelch potentially
significant research into the causes of breast cancer,
particularly those that are modifiable. It is therefore advisable
to proceed cautiously with the conduct of and, particularly,
the interpretation of studies designed to examine the effects
of common SNPs on breast cancer risk, particularly in the
absence of consideration of exposures. This is an exciting
age of progress in and discovery of the role that the human
genome plays in disease risk and outcome, and there is hope
that the convergence of genomic approaches and molecular
epidemiologic studies of gene–environment interactions will
provide growing insight into the causes of and, importantly,
the prevention of breast cancer.
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